| Jennifer Friley, | |
|
4676 Chutney Dr, Antioch, TN 37013-1634 | |
| (615) 554-3879 | |
| Not Available |
| Full Name | Jennifer Friley |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 4676 Chutney Dr, Antioch, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114522521 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 28558 (Tennessee) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ipc Pac Healthcare Services Of Tennessee Pc | 0840587572 | 64 |
News Archive
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).
HudsonAlpha Institute for Biotechnology today announced it has purchased the HiSeq X Ten sequencing system manufactured by Illumina, Inc. The technology will enable HudsonAlpha to produce and analyze genomic data faster and at a lower cost. The purchase stems from the Institute's commitment to research programs for genomics excellence in patient care.
One of the main tools doctors use to detect diseases and injuries in cases ranging from multiple sclerosis to broken bones is magnetic resonance imaging.
An analysis of US data from 2011 indicates that nearly 29 percent of cancer survivors are financially burdened as a result of their cancer diagnosis and/or treatment. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also reveals that such hardships can have lasting physical and mental effects on cancer survivors.
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
› Verified 5 days ago
| Entity Name | Ipc Pac Healthcare Services Of Tennessee Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104277656 PECOS PAC ID: 0840587572 Enrollment ID: O20160928000541 |
News Archive
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).
HudsonAlpha Institute for Biotechnology today announced it has purchased the HiSeq X Ten sequencing system manufactured by Illumina, Inc. The technology will enable HudsonAlpha to produce and analyze genomic data faster and at a lower cost. The purchase stems from the Institute's commitment to research programs for genomics excellence in patient care.
One of the main tools doctors use to detect diseases and injuries in cases ranging from multiple sclerosis to broken bones is magnetic resonance imaging.
An analysis of US data from 2011 indicates that nearly 29 percent of cancer survivors are financially burdened as a result of their cancer diagnosis and/or treatment. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also reveals that such hardships can have lasting physical and mental effects on cancer survivors.
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
› Verified 5 days ago
| Entity Name | Christopher Dennis Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588090229 PECOS PAC ID: 7416254990 Enrollment ID: O20190327000812 |
News Archive
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).
HudsonAlpha Institute for Biotechnology today announced it has purchased the HiSeq X Ten sequencing system manufactured by Illumina, Inc. The technology will enable HudsonAlpha to produce and analyze genomic data faster and at a lower cost. The purchase stems from the Institute's commitment to research programs for genomics excellence in patient care.
One of the main tools doctors use to detect diseases and injuries in cases ranging from multiple sclerosis to broken bones is magnetic resonance imaging.
An analysis of US data from 2011 indicates that nearly 29 percent of cancer survivors are financially burdened as a result of their cancer diagnosis and/or treatment. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also reveals that such hardships can have lasting physical and mental effects on cancer survivors.
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
› Verified 5 days ago
| Entity Name | Nv Pacs 2 Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427534809 PECOS PAC ID: 0941550578 Enrollment ID: O20210903001263 |
News Archive
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).
HudsonAlpha Institute for Biotechnology today announced it has purchased the HiSeq X Ten sequencing system manufactured by Illumina, Inc. The technology will enable HudsonAlpha to produce and analyze genomic data faster and at a lower cost. The purchase stems from the Institute's commitment to research programs for genomics excellence in patient care.
One of the main tools doctors use to detect diseases and injuries in cases ranging from multiple sclerosis to broken bones is magnetic resonance imaging.
An analysis of US data from 2011 indicates that nearly 29 percent of cancer survivors are financially burdened as a result of their cancer diagnosis and/or treatment. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also reveals that such hardships can have lasting physical and mental effects on cancer survivors.
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jennifer Friley, 4676 Chutney Dr, Antioch, TN 37013-1634 Ph: (615) 554-3879 | Jennifer Friley, 4676 Chutney Dr, Antioch, TN 37013-1634 Ph: (615) 554-3879 |
News Archive
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).
HudsonAlpha Institute for Biotechnology today announced it has purchased the HiSeq X Ten sequencing system manufactured by Illumina, Inc. The technology will enable HudsonAlpha to produce and analyze genomic data faster and at a lower cost. The purchase stems from the Institute's commitment to research programs for genomics excellence in patient care.
One of the main tools doctors use to detect diseases and injuries in cases ranging from multiple sclerosis to broken bones is magnetic resonance imaging.
An analysis of US data from 2011 indicates that nearly 29 percent of cancer survivors are financially burdened as a result of their cancer diagnosis and/or treatment. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also reveals that such hardships can have lasting physical and mental effects on cancer survivors.
Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, Eq, 1.4 mg/0.36 mg and 5.7 mg/1.4 mg Base. Actavis' ANDA product is a generic version of Orexo's Zubsolv, which is a partial opioid agonist indicated for the maintenance treatment of opioid dependence.
› Verified 5 days ago
Mrs. Rachel Benz Grace, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4200 Murfreesboro Pike, Antioch, TN 37013 Phone: 615-501-3500 | |
Mrs. Joelle M Krizner, N.P. Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 5801 Crossings Blvd, Antioch, TN 37013 Phone: 615-941-8501 Fax: 615-941-8102 | |
Candius G Loggins, APN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 5801 Crossings Blvd, Antioch, TN 37013 Phone: 615-851-9401 | |
Miss Natsai Laurah Zhou, FNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2929 Old Franklin Rd, # 809, Antioch, TN 37013 Phone: 615-243-0776 | |
Michelle Aubrie Feneck, RN, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2788 Murfreesboro Pike, Antioch, TN 37013 Phone: 714-329-7594 | |
Mrs. Mendy A Hicks, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 5801 Crossings Blvd, Antioch, TN 37013 Phone: 615-941-8501 Fax: 615-941-8502 |